Attendees at the event can join the Roquette team to discover the latest innovations in direct compression technology
France-based food company Roquette has announced its plans to take direct compression formulation to the next level with the launch of two new mannitol products at this year’s edition of CPHI.
In addition, the company will demonstrate its commitment to unlocking healthier futures with a focus on patient centricity. As a sponsor of this year’s conference program, visitors are invited to join Roquette experts for a number of exclusive presentations, highlighting topics including solutions to tackle medication non-adherence and optimization of drug delivery systems with the right high-quality excipients.
Roquette has invited attendees at CPHI to discover the potential of high quality mannitol-based products designed to unlock innovative application areas, like controlled release tablets, and optimise direct compression processes.
“As a leading global pharmaceutical excipients supplier, it’s important for us to continuously harness the power of innovation to support our customers’ evolving formulation needs,” said Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette.
Drug adherence is a significant issue today, with medication non-adherence accounting for half of all treatment failures in the USA. That’s why we’re putting patient centricity in the spotlight
“We’re delighted to bring two brand-new solutions to the market that will open up new development opportunities in the direct compression space. We’ve spent significant time understanding our customers’ pain points, as well as those of the wider industry, so we can bring these specialised products to fruition and help to solve some of the toughest drug delivery challenges,” continued Smaltz.
For oral formulations, taste, appearance, and smell have a direct impact on medication adherence. This not only limits patients from leading a healthy life, but also affects the commercial bottom line. Smaltz added: “Drug adherence is a significant issue today, with medication non-adherence accounting for half of all treatment failures in the USA. That’s why we’re putting patient centricity in the spotlight; we believe the world needs access to more innovative drug delivery systems and applications that support patient compliance. Achieving this vision demands all of our participation and CPHI is the perfect platform through which to share this message.”
On November 3, Roquette will take centre stage as part of the ‘Patient Centricity’ track. Smaltz, alongside other industry experts, will participate in a roundtable exploring the latest news and insights on consumer health, including how the pharmaceutical industry can better engage patients in education and decision-making. Arnaud Verhaeghe, Head of Oral Dosage at Roquette will then present the latest innovations addressing patient compliance and enhancing consumer experience.
The company can be found at stand 80C90.